Insider Buying: Nuvilex (NASDAQ:PMCB) Director Acquires 20,000 Shares of Stock

Nuvilex Inc. (NASDAQ:PMCB) Director Jonathan Schechter acquired 20,000 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were bought at an average cost of $0.78 per share, for a total transaction of $15,600.00. Following the transaction, the director directly owned 152,500 shares in the company, valued at approximately $118,950. This represents a 15.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jonathan Schechter also recently made the following trade(s):

• On Wednesday, January 7th, Jonathan Schechter bought 20,000 shares of Nuvilex stock. The stock was purchased at an average cost of $0.84 per share, with a total value of $16,800.00.

Nuvilex Trading Up 7.5%

PMCB stock traded up $0.06 during trading on Wednesday, reaching $0.83. 296,817 shares of the stock were exchanged, compared to its average volume of 292,514. The firm’s 50 day moving average is $0.85 and its 200 day moving average is $0.95. The firm has a market cap of $8.41 million, a P/E ratio of -0.60 and a beta of 0.04. Nuvilex Inc. has a twelve month low of $0.63 and a twelve month high of $1.90.

Nuvilex (NASDAQ:PMCB) last released its quarterly earnings data on Thursday, December 18th. The company reported ($0.32) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Nuvilex in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.